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Efficacy and Safety of Low Dose Amiodarone for Management of
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KAWANO ET AL.: Efficacy and Safety of Low Dose Amiodarone for Management of Tachyarrhythmias in Japanese
Patients. Background: The major concern during amiodarone (AMD) therapy is the adverse effects including
pulmonary toxicity. However, low dose AMD may reduce the side effects without loss of anti-arrhythmic efficacy.
The aim of this study is to investigate the efficacy and safety of low dose AMD therapy for tachyarrhythmias.
Methods and Results: AMD was given in 84 patients (60 males, mean age 66 years) with atrial and/or ventricular
tachyarrhythmias and left ventricular dysfunction (mean ejection fraction:0.26±0.12). The major underlying diseases
were ischemic heart disease (36) and dilated cardiomyopathy (27). Mean follow-up period was 15±14.1 months.
Oral AMD was initially loaded 400 mg daily for 3 days and then maintained between 50 to 200 mg daily. Follow-up
examination was performed before and after oral AMD at 1, 3, 6 and every 6 months. Efficacies for arrhythmias were
evaluated by symptoms, standard 12-leads ECG, and ambulatory ECG. Mean initial dose was 200±106.8 mg and
maintenance dose was 100±62.6 mg daily. During follow-up period, targeted tachyarrhythmias were successfully
suppressed in 66 (78.6%) of 84 patients. Adverse effects were observed in 16 patients (19.0%); thyroid dysfunction
(11.9%), liver dysfunction (2.4%), pulmonary toxicity, finger tremor, hypogeusia and sinus bradycardia, respectively
(1.2%). Pulmonary toxicity was not lethal and no progression was observed with reducing use of AMD.
Conclusion: Low dose AMD therapy was effective for suppression of tachyarrhythmias with impaired cardiac
function and safely administered with few serious complications. (J HK Coll Cardiol 2009;17:19-26)
Adverse effects, amiodarone, low dose administration
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Introduction

Combination Drugs

Amiodarone (AMD) is known to be effective for
atrial fibrillation (AF), atrial flutter (AFL), and
ventricular tachyarrythmias (ventricular tachycardia:
VT, ventricular fibrillation: VF). 1-4 It could be
administered to patients with cardiac dysfunction
because of less negative inotropic and proarrhythmic
effects. However, the adverse effects including
pulmonary toxicity are always major concern.
In previous studies in Western countries,5-14 it has
been reported that low dose AMD therapy was well
tolerated and maintained long-term suppression of
arrhythmias. Besides, it may reduce the risk of adverse
complications. However, in Japanese patient population,
no study has been conducted whether the appropriate
lower dose of AMD could be effective and safe or not.
We hypothesized that appropriate low dose AMD
therapy for Japanese patients may be effective and also
reduce the incidence of adverse effects. We evaluated
retrospectively the clinical efficacy and safety of lower
dose AMD therapy in patients with tachyarrhythmias
and cardiac dysfunction.

Beta blocker were used in 44 patients (52.4%),
angiotensin-converting enzyme inhibitors (ACE-I) in
40 (47.6%), angiotensin II receptor blocker (ARB) in
23 (27.4%), digitalis in 38 (45.2%). These drugs had
already been administered before the initiation of AMD
or simultaneously in some patient.

Study Design
In Western countries, it is recommened that initial
dose of oral AMD is 600 to 800 mg daily over 1 week
(occasionally, it exceeds 1000 mg daily) and
maintenance is 200 mg daily. Also, in our country, initial
dose of oral AMD is recommened as 400 mg daily for
2 weeks and maintenance dose is recommened as
200 mg daily. In this study, oral AMD was loaded with
initial dose of 400 mg daily for 3 days and then
maintained 50 to 200 mg daily. The minimal dose was

Table 1. Characterisics of Patients
No. of pateints

84

Male

60

Age (years)

66±13

EF

0.26±0.12

Study Subjects (Table 1)

Follow-up (range) (months)

15±14 (6-71)

Eighty-four patients (60 male, 24 female, mean
age 66±13.0 year old) with VT, VF, AF, and AFL
were enrolled in this study. All patients had cardiac
dysfunction and the mean left ventricular ejection
fraction (LVEF) measured by 2D-echocardiography
was 0.26±0.12. Mean follow-up period was 15±14.1
months ranging 6 to 71 months. In this series, 36
patients had ischemic heart disease (IHD) and 48
patients had non-ischemic heart disease (NIHD). In
NIHD group, there were 27 dilated cardiomyopathy
(DCM), 4 state after myocarditis, 3 hypertrophic
cardiomyopathy, 3 cardic sarcoidosis, and others
(Fabry disease, mitral regurgitation, tachycardia
induced cardiomyopathy, and unknown). VT were
observed in 70 patients with 40 sustained, 30 non
sustained, and VF in 3, AF in 14, AFL in 2. There
were 5 patients overlapping VT and AF.

Underlying heart disease

Methods

20

Ischemic HD

36

Non-ischemic HD

48

Arrhythmias
VT/VF

73

AF

14 (5 overlap with VT)

AFL

2

Combination drugs
Beta blocker

44

ACE-I

40

ARB

23

ACE-I: angiotensin converting enzyme inhibitor; AF: atrial
fibrillation; AFL: atrial flutter; ARB: angiotensin II receptor
blocker; EF: ejection fraction; HD: heart disease; VF:
ventricular fibrillation; VT: ventricular tachycardia
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defined as the effective maintenance dose. In some cases
(non sustained VT with low incidence and stable
hemodynamic state, AF and AFL), maintenance dose
was started without initial loading. Mean initial loading
dose was 200±106.8 mg and maintenance dose was
100±62.6 mg daily. Standard 12 leads ECG, ambulatory
ECG, Chest X-P and computed tomography (CT),
echocardiography, and ophthalmologic examination
were performed before and after administration of oral
AMD at 1, 3, 6 and every 6 months. Complete blood
cell counts, biochemistry and thyroid function, serum
concentration of AMD, dysethyl-amiodarone (DEA),
KL-6, and brain naturiuretic polypeptide (BNP) were
also measured.
The efficacy for tachyarrhythmias was
evaluated by clinical symptoms and the results of
repeated ambulatory ECG. In selected cases with
sustained VT, after obtained written informed consent
and, the efficacy was evaluated by electrophysiologic
study performed at 4 weeks after administration of
AMD. The efficacy was actually defined as success
in suppression for arrhythmias without increase of
the maintenance dose (maximum 200 mg daily) of
AMD, and without any additional combination of

Low dose AMD successfully treated 75.3% of patients with VT
and VF, and 100% of patients with AF or AFL. Overall, AMD
was successful in 78.6% of patients with tachyarrhythmias.

Figure 1. Efficacy of low dose AMD for tachyarrhythmias.
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anti-arrhythmic drugs. If the complete suppression
for sustained VT/ VF, more than 50% reduction of
non-sustained VT or the elimination of consecutive
ventricular premature complexes were recognized,
AMD was considered to be effective. Moreover, in
patients with implantable cardioverter defibrillator
(ICD), even if the cycle length of VT prolonged after
initiation of AMD and VT could be terminated by
anti-tachycardia pacing without cardioversion, AMD
was considered to be effective.

Results
Anti-arrhythmic Efficacy of Low Dose AMD
Therapy (Figures 1 & 2)
In total 84 patients, low dose AMD was given
in 73 patients with 30 non-sustained and 40 sustained
VT or 3 VF. In 55 (75.3%) of them, it effectively
suppressed those arrhythmias. An effective ratio in
non sustained and sustained VT had no difference
with 76.7% and 72.5%. Also, in the comparison with
29 IHD and 44 NIHD, it was a little higher in IHD
(82.7%) than NIHD (70.5%), but there was no

In patients that did not respond to low dose AMD, there were
4 adverse effects (22.2%): liver dysfunction, neurological
toxicity, and gastrointestinal effects. No efficacy was recorded
in 2 patients (11.1%), who required discontinuation of AMD
therapy. AMD dose was increased to ≥200 mg/day in
5 patients (27.8%), and additional combination drugs were
required for 7 patients (38.9%).

Figure 2. Non-responders to low dose AMD therapy.
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significant difference. In 12 of 55 patients, ICD was
required simultaneously with initiation of AMD for
preventing sudden cardiac death. No recurrences of VF
were observed after administration of AMD. In
4 of 12 patients with ICD, sustained VT was recognized
but they were terminated by anti-tachycardia pacing
without cardioversion.
Low dose AMD was also given in 14 patients with
persistent AF and 2 patients with persistent AFL.
Persistent AF or AFL was defined to last for 48 hours
or more.15 Electrical cardioversion was performed in
patients with long lasting AF or AFL (>3 months ) after
treatment of AMD. Although 5 patients with AF and
2 with AFL were performed electrical cardioversion,
9 out of 14 AF spontaneously restored to sinus rhythm
within a month after administration of AMD. During
follow-up period, sinus rhythm was maintained and
there was no recurrence of AF and AFL. Eventually the
anti-arrhythmic efficacy by our protocol was rated to
78.6%.
Finally, 18 patients were judged as no efficacy
in our protocol. AMD was discontinued in 6 patients
because of adverse effects in 4 and no efficacy in 2.
Five patients with maintenance dose of 100 mg daily
have required increasing the dose up to 200 mg or more,
and 7 patients were needed additional combination drugs
(6 mexiletine, 1 aprindine).

Adverse Effects
Adverse effects were observed in 16 out of 84
patients (19.0%); pulmonary toxicity in 1, thyrotoxicosis
in 1, hypothyroidism in 9, liver dysfunction in 2,
neurological toxicity in 1, gastrointestinal adverse effect
in 1, and sinus bradycardia in 1.
Non-lethal pulmonary toxicity was observed in
a 68-year-old male patients. He had DCM with left
ventricular EF of 0.25 and non-sustained VT. AMD
was initially loaded 400 mg daily for 3 days and then
maintained 200 mg daily according to the protocol.
Subsequently, non-sustained VT was successfully
suppressed and there were no respiratory symptoms.
No significant changes in serum concentration of KL-6,
AMD, and DEA were observed. However, patchy
interstitial infiltration was recognized on 1-year
follow-up of chest X-P and CT. Serum concentration
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of KL-6 concomitantly increased to 737 pg/ml
(normal range: <500 pg/ml). This pulmonary toxicity
was not lethal, and after reduction of AMD to 100 mg
daily, neither progression nor recurrence of arrhythmia
was noted.
Thyroid dysfunction was the most prevalent side
effects and it was recognized in 10 of those 16 patients.
In this study, thyroid dysfunction was defined as state
that serum thyroid stimulating hormone (TSH) level was
more than 10.0 µIU/ml or less than 0.01 µIU/ml (normal
range: 0.56-4.3), and as that the patients required any
medication with some symptoms due to thyroid
dysfunction. Thyrotoxicosis was observed in a 24 yearold female patient of chronic myocarditis with nonsustained VT (LVEF: 0.3). Initial dose of AMD was
200 mg daily for 3 days and maintenance dose was
100 mg daily. Two years later, serum level of TSH was
less than 0.1 µU/ml and serum level free T3, free T4 was
elevated and asymptomatic thyrotoxicosis was
recognized. Serum concentration of AMD and DEA was
not elevated. Approximately 6 months after reduction
of AMD to 50 mg daily, thyroid function was developed
hypothyroidism without medication and then gradually
restored to euthyroid state. Hypothyroidism was
recognized in 9 patients with mean follow-up period of
12.9 months after administration of AMD. Patients with
hypothyroidism had no symptoms and after maintenance
dose reduction or supplement with L-thyroxine, no
progression had noted and none of them was
discontinued AMD.
Liver dysfunction was observed in 2 patients
whose aminotransferase rose above 300 IU/l within
1 week after initiation of AMD. Finger tremor and
hypogeusia was recognized in each 1 patients at
1 month and 17 months after administration of AMD,
respectively. However, these adverse complications
gradually improved after discontinuation of AMD. Sinus
bradycardia required implantation of pacemaker was
observed at 3 months after treatment. Corneal microdeposits related the AMD were observed in almost
patients, but no visual disturbances were found. There
were no dermatologic adverse effects.
No difference was observed between atrial and
ventricular tachyarrhythmias or IHD and NIHD on the
safety by low dose AMD.
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Serum Concentration of AMD, DEA, KL-6,
Thyroid Hormones, and BNP
Mean serum concentration of AMD and DEA had
been rising for 3 months after administration and then
leveled off. Mean concentration at 2 years were
505±273.6 ng/ml, 331±134.9 ng/ml, respectively. In
5 of 84 patients, serum concentration of AMD rose
above 1000 ng/ml at 3 months (maximum value: 1687
ng/ml). In these patients, 3 were female, and there were
no significant difference in initial and maintenance dose
and combination drugs compare to other patients. One
female patient had primary biliary cirrhosis, and it was
considered as a cause of highly elevated serum
concentration of AMD.
D u r i n g f o l l ow - u p p e r i o d , m e a n s e r u m
concentration of KL-6 didn't increase more than
500 pg/ml except with 2 patients. One of these 2 patients
had pulmonary toxicity, and after reduction of AMD,
KL-6 was normalized.
Regarding with the thyroid toxicity, average TSH
level increased gradually with time course, but it was
transient and decreased after 18 months. Free T3 and
T 4 had not significantly changed. Mean serum
concentration of BNP decreased from 348±434.9 to
154±497.5 pg/ml within 1 month after administration
of AMD and then the level was maintained in almost
patients.

ECG Parameters and Cardiac Function
ECG measurement values such as PR interval,
QRS duration and QT interval had no significant
changes. RR interval was increased from 0.72±0.20
sec to 0.92±0.12 sec for 6 months after initiation
and then leveled off. Baseline mean LVEF on
echocardiography was 0.26±0.11. Individual LVEF
was 0.25±0.12 in sustained VT, 0.27±0.10 in non
sustained VT, 0.3±0.2 in VF, and 0.32±0.14 in AF,
AFL. Also, it was 0.32±0.11 in IHD, 0.21±0.11 in
NIHD, 0.29±0.12 in effective group and 0.20±0.11
in non-effective group, respectively. No significant
changes of LVEF were observed during follow-up
period.

Prognosis
During follow-up period, we lost 17 patients
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because of heart failure in 14, bacterial pneumonia,
colon cancer and suicide in 1, respectively. Further
details of 14 patients with heart failure, there were 11
NIHD and 3 IHD. LVEF was not different in both groups
(0.24±0.12 vs 0.24±0.10). Cardiac resynchronization
therapy was performed in 6 of 14 patients with
intractable or drug-refractory heart failure. There were
no sudden cardiac death and no death as a result of the
adverse effects associated with AMD.

Discussion
AMD is the leading anti-arrhythmic drug, which
highly effective for suppression and prevention of
arrhythmias, however, the adverse effects including
pulmonary toxicity are always major concern. The
previous and recent studies revealed that low dose
AMD could be effectively applied without serious
complication.5-14
In this study, the dose of AMD is set much lower
than those reported conventional dosage. The results
suggest that the appropriate low dose AMD in our
protocol is acceptably effective and safe.

The Efficacy of Low Dose AMD Therapy
Low dose AMD successfully suppressed 75.3%
of VT and VF (72.5% of sustained VT, 76.7% of nonsustained VT and 100% of VF), 100% of AF and AFL
in this study and favorable results were obtained
although the increase of the serum concentration of
AMD and DEA was gradual. From the perspective of
IHD and NIHD, the efficacy in IHD (82.7%) was a little
higher than the one in NIHD (70.5%), but no significant
difference was observed. In this study, several reasons
were considered why low dose AMD was effective.
The first reason is beta-blocking action of AMD,
which indirectly affects the electrophysiologic
properties of myocardium. Unlike the standard betablocking drugs, the blocking action of AMD to the betaadrenergic receptors is noncompetitive and additive. It
results from inhibition of adenylate cyclase formation
and from a reduction in the number of beta-adrenergic
receptors.16
The second one is the interactive and synergistic
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effect with combination drugs, ACE-I, ARB and
standard beta-blockers. Approximately 70% of patients
were started ACE-I or ARB and 50% were started with
beta-blocker before or at the same time of AMD
administration. Particularly, AMD combined with betablocker was effective for ventricular tachycardia and
prevention of arrhythmic death. 17,18 Although some
studies reported the effectiveness for AF by combination
of AMD with ACE-I or ARB, no studies showed the
efficacy for ventricular arrhythmias with such
combinations.19,20 Considering the effect of ACE-I or
ARB inhibited on sudden cardiac death,21,22 it seemed
that AMD combined with these drugs was much
effective for lethal arrhythmias.
The third one is pharmacokinetic characteristics
of AMD. AMD is quite lipophilic and it may account
for the unusual pharmacokinetic feature. Usually, AMD
is known to slowly distribute to the tissues because of
incompletely absorption when oral administration was
made. It results in a requirement of very long loading
periods, up to several months, before reaching steadystate tissue concentration. Besides AMD is taken up very
extensively by tissue, with marked inter-individual
variation.2,14
During long-term therapy, an effect of DEA, the
metabolite of AMD, also increases like the mother drug
and the effect of AMD becomes more complicated. It
has been shown that the amount of DEA accumulated
in the myocardium after several weeks of initiation of
oral AMD is comparable to, or greater than, that of
AMD. Also there is a species difference in the extent of
myocardial accumulation of DEA.23
Electrophysiologically, it has been shown that the
effects of oral AMD on sinoatrial and AV nodal function
are maximal within 2 weeks, whereas the effects on VT
and ventricular refractoriness tend to emerge more
gradually, becoming maximal over than 10 weeks.14
In our study, the effects on ventricular arrhythmias
seemed to develop within 1-2 weeks after oral AMD.
Theoretically, this is controversial results and further
interpretation might be done that AMD and DEA
distribute myocardium and give anti-arrhythmic effects
before reaching steady-state serum concentration.
The fourth reason is that the patients could keep
the inactive state by admission. All patients treated with
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AMD were required to hospitalization and they have to
be keeping rest. Therefore, the relief of physical or
mental stresses possibly reduce the incidence of
tachyarrhythmias nevertheless the insufficient
distribution of AMD to myocardial tissue.
The fifth reason is the amelioration of heart
failure. In patients with acute heart failure, the treatment
started concomitantly with loading low dose of AMD.
It is possible that the improvement of acute heart failure
contributed to sufficient reduction of arrhythmias. As
the final reason, a racial difference to AMD sensitivity
might be considered. Although no studies were
conducted about a relation between AMD and racial
difference, we may take it into account because even
much lower dose AMD than previous reports was
effective. Thus, we thought that the acute and partly
chronic effects of low dose AMD were contributed to
synergistic effects of beta-blocking action, the
interactive and synergistic effects with combination
drugs, keeping inactive state, a treatment for heart failure
or racial difference on AMD sensitivity.
It has been reported that there is wide inter-patient
variability between the serum concentration of AMD
and the efficacy or toxicity. This incompatibility
explains that the clinical reliability of serum
concentration of AMD has been limited.2 Actually, the
efficacy of low dose AMD in chronic phase does not
always correlate with serum concentration level of AMD
and the efficacy for arrhythmias should be evaluated by
clinical symptoms and ambulatory ECG.

The Safety of Low Dose AMD Therapy
Adverse effects were observed in 16 (19.0%) out
of 84 patients in this study.
In detail, we had experienced pulmonary toxicity
in one patient (1.2%), hypothyroidism in 9 patients
(10.7%), thyrotoxicosis in 1 patient (1.2%). The
incidence of pulmonary toxicity has been reported to
be about 6% to 8%.2,24,25 It was lower than previous
studies in our protocol. Pulmonary toxicity is, however,
the most considerable adverse effect. It has been
reported that mild to fatal pulmonary toxicity such as
adult respiratory distress syndrome can occur even
with low dose AMD therapy. 26 In our study, non
lethal pulmonary toxicity occurred one year after

April 2009

J HK Coll Cardiol, Vol 17

KAWANO ET AL.

administration of AMD and after reduction of AMD,
neither progression of pulmonary fibrosis nor recurrence
of arrhythmias was recognized.
The incidence of hyper- or hypothyroidism is
reported approximately 2% to 13% and 6 to 13%,
respectively. 27,28 It was equivalent to these studies
despite of our appropriate lower dose protocol. In one
study, most Japanese patients with AMD induced
thyrotoxicosis exhibit type 2 hyperthyroidism.29 This
type 2 AMD induced thyrotoxicosis is known to occur
in the apparently normal thyroid, and results from a
direct toxic effect of the drug on the thyroid tissue.
It is often difficult to predict the onset of type 2
thyrotoxicosis because it may develop at anytime during
treatment with AMD causing destructive thyroiditis with
leakage of stored thyroid hormones into the circulation.27
On the other hand, AMD induced hypothyroidism was
usually not clinical concern because none of those
patients discontinued AMD through the reduction of
AMD or the supplement with L-thyroxine.
Liver dysfunction is also common adverse
complication with AMD. Elevation of serum
aminotrasferase is generally noted in 25% of patients
on long-term treatment.30 In this study, we experienced
liver dysfunction in 2 patients within 1 week after
initiation of AMD. These cases had no underlying
disease, except for heart disease. We speculated that
the mechanism of acute liver dysfunction might be
idiosyncratic sensitivity to AMD.
Even in those cases with adverse effects, no
significant changes in serum concentration of AMD and
DEA were observed and no serious complications were
developed during follow-up period in this study.
However, the incidence of adverse effects increased over
time, and adverse effects may be related to the total
amount of AMD accumulation. Many of the minor
adverse effects are reported to be dose-related, but
serious toxicity is often unrelated to the dose and is
unpredictable. Regular laboratory examination can help
the detection of potential problems and the abnormal
findings can be observed preceded to the development
of clinical symptoms.2 It has been reported that highresolution CT used in prone positions as well as a supine
position could be an effective technique for preventing
the clinically serious pulmonary toxicity by AMD.31
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Therefore, to prevent the serious adverse complication
in patients with long-term AMD treatment, routine
screening of organic toxicity is very important.

Study Limitations
The result of this study must be carefully
interpreted because the study was done in nonrandomized and retrospective fashion, and sample size
and follow-up period were not enough. Particularly the
cumulative dose of AMD play an important role for the
cause of adverse effect; therefore, we should always
pay attention to the potential adverse effects during longterm follow-up period.

Conclusion
Appropriate low dose AMD for tachyarrhythmias
was effectively administered with few adverse
complications. However, careful observation during
long-term follow-up is mandatory for the detection of
unpredictable complications .
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